ANI Pharma (ANIP) Tops Q3 EPS by 12c, Reaffirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance
November 6, 2018 8:30 AM ESTBAUDETTE, Minn., Nov. 6, 2018 /PRNewswire/ --
For the third quarter 2018:
Record net revenues of $50.7 million, an increase of 5% as compared to the same period in 2017 GAAP net income of $5.0 million and diluted GAAP earnings per share of $0.42 Adjusted non-GAAP EBITDA of $21.4 million Adjusted non-GAAP diluted earnings per share of $1.29ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported its financial results for the three and nine months ended September 30, 2018 and reaffirmed its 2018 financial guidance. The Company will... More
